Phase 2 Trial Using rhDNase to Reduce Mortality in COVID-19 Patients With Respiratory Failure
This study tests whether a medication called Dornase Alpha (rhDNase), delivered through a nebulizer to the lungs, can help COVID-19 patients who are experiencing severe breathing problems. Researchers will compare patients who receive this medication to those who receive a placebo (inactive treatment) to see if it reduces deaths within 28 days and is safe to use.
Key Objective: The trial is testing whether nebulized rhDNase can reduce 28-day mortality and improve survival in COVID-19 patients with respiratory failure.
Who to Consider: COVID-19 patients who are hospitalized with respiratory failure and requiring supplemental oxygen or ventilator support should consider enrolling.
Trial Parameters
Brief Summary
This Phase 2 Randomized Placebo Controlled Trial will determine if administering nebulized Dornase Alpha (rhDNase) to COVID-19 patients with respiratory failure is safe and will reduce 28-day mortality.
Eligibility Criteria
Inclusion Criteria: 1. Male or Female age 18 or older 2. On high flow oxygen =/\> 6 liters nasal cannula (or) 3. On mechanical ventilation 4. Clinical diagnosis of COVID-19 \& positive PCR test (or) 5. Clinical diagnosis of COVID-19 \& negative PCR test with clinical symptoms of COVID-19 and pathognomonic lesions on a chest CT scan Exclusion Criteria: 1. Known allergy to Pulmozyme 2. Less than 18 years of age 3. Grave condition with anticipated death within 48 hours; at the discretion of treating physician. 4. Enrollment in another clinical trial receiving investigatory drugs